REG - IXICO plc - Notice of Capital Markets Day

About this update from Atreyu Capital Markets Ltd.

RNS Number : 2865B IXICO plc 30 September 2025 IXICO plc("IXICO", the "Company" or the "Group")Notice of Capital Markets Day30 September 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces it will be hosting a Capital Markets Day for analysts and institutional investors between 14:00 - 17:00 GMT on 30 October 2025 at the offices of Cavendish Capital Markets.The event will provide the opportunity to hear from IXICO's CEO and strengthened senior management team, key customers and industry opinion leaders. The agenda will explore the Company's growth strategy and future direction, the neuroscience landscape trends and expansion opportunities for the Company, IXICO's technology roadmap and a detailed explanation of IXICO's AI-driven precision medicine technology platformExisting and prospective retail investors are welcome to join via a live webcast. The facility to submit questions will be available on this platform.To register your interest please contact Cavendish Capital Markets on +44 (0) 20 7220 0500 or via email [email protected] register for the live webcast investors can sign up to Investor Meet Company for free and add to meet IXICO PLC via: https://www.investormeetcompany.com/ixico-plc/register-investorEndsFor further information please contact:IXICO plc+44 (0) 20 3763 7499Grant Nash, Chief Financial OfficerJames Chandler, Chief Business OfficerCavendish Capital Markets Limited(Nominated Adviser and Sole Broker)+44 (0) 20 7220 0500Giles Balleny / Isaac Hooper (Corporate Finance)Nigel Birks (Healthcare Specialist Sales)Harriet Ward (Corporate Broking)Michael F Johnson (Sales)About IXICO www.IXICO.comIXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds o...

View stock analysis, news, and events for Atreyu Capital Markets Ltd.